Fabricant chinois de poudre de stéroïdes anabolisants
EnglishAfrikaansБългарскиNederlandsFrançaisDeutschItaliano日本語LatīnaNorskپارسیPolskiPortuguêsRomânăРусскийSlovenčinaSlovenščinaEspañolSvenskaTürkçeУкраїнськаудмурт кыл

Stéroïdes féminins

» Stéroïdes crus » Stéroïdes féminins

  • Caractéristiques
  • Description du produit
  • Utilisation du produit
Nom du produit Altrenogest
n ° CAS. 850-52-2
MF C21H26O2
MW 310.44
EINECS Non. 212-703-1
Densité 1.0865 (estimation approximative)
Point d'ébullition 390.58°C (estimation approximative)
Point de fusion 120°

(1)Altrenogest is indicated (labeled) to suppress estrus in mares to allow a more predictable occurrence of estrus following withdrawal of the drug. It is used clinically to assist mares to establish normal cycles during the transitional period from anestrus to the normal breeding season often in conjunction with an artificial photoperiod. It is more effective in assisting in pregnancy attainment later in the transition period. One group of authors (Squires et al. 1983) suggest selecting mares with considerable follicular activity (mares with one or more follicles 20 mm or greater in size) for treatment during the transitional phase. Mares that have been in estrus for 10 days or more and have active ovaries are also considered to be excellent candidates for progestin treatment.

(2)Altrenogest is effective in normally cycling mares for minimizing the necessity for estrus detection, for the synchronization of estrus and permitting scheduled breeding. Estrus will ensue 2-5 days after treatment is completed and most mares ovulate between 8-15 days after withdrawal. Altrenogest is also effective in suppressing estrus expression in show mares or mares to be raced. Although the drug is labeled as contraindicated during pregnancy, it has been demonstrated to maintain pregnancy in oophorectomized mares and may be of benefit in mares who abort due to sub-therapeutic progestin levels.

The pharmacodynamic activity of altrenogest has been demonstrated in a number of animal models. Altrenogest also has weak oestrogenic, anabolic and androgenic effects, but has no corticoid or anti-inflammatory effects.

They transform proliferative endometrium to secretory endometrium, enhance myometrium hypertrophy and inhibit spontaneous uterine contraction. Progestins have a dosedependent inhibitory effect on the secretion of pituitary gonadotropins and also have some degree of estrogenic, anabolic and androgenic activity.

Altrenogest (or allyltrenbolone) is a synthetic trienic C21 steroidal progestomimetic, belonging to the nortestosterone series. It is an orally active (pro)gestagen. Like all steroids, altrenogest acts by its liposolubility by penetrating the target cells where it binds to specific receptors.

formulaire ( nous vous répondrons dans les plus brefs délais )

Nom:
*
E-mail:
*
Message:

Vérification:
1 + 6 = ?

Peut-être que vous aimez aussi

  • Notre avantage

    Bon prix

    Haute qualité

    Livraison rapide

    Expédition sécurisée

    Excellent service après-vente

  • Entrepôt local

    Entrepôt UE

    Entrepôt au Royaume-Uni

    Entrepôt aux États-Unis

    Canada Entrepôt

    Australie Entrepôt

  • Mode de paiement

    Pay Pal

    Bitcoin

    Virement bancaire

    Gramme d'argent

    Western union

  • Nous contacter

    E-mail: jacob@steroid-peptide.com

    Whatsapp: +8615636286252

    Téléphoner: 0086-15636286252

    Site Internet: www.steroid-peptide.com

    Bienvenue votre enquête